Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching

Vaccine

Volumn 29, Issue 17, 2011, Pages 3276-3283

  Rehm, Kristina E ^a   Roper, Rachel L ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Antibody; Poxvirus; T lymphocyte

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; LIVE VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFICACY; FEMALE; GENE DELETION; GENE REARRANGEMENT; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SPLEEN CELL; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS A35 GENE; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; CHICK EMBRYO; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; IMMUNOGLOBULIN CLASS SWITCHING; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; SMALLPOX; SMALLPOX VACCINE; SPLEEN; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 79954613312     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.023     Document Type: Article

References (51)

1. Mahalingam S., Damon I.K., Lidbury B.A. 25years since the eradication of smallpox: why poxvirus research is still relevant. Trends Immunol 2004, 25(December (12)):636-639.
2. Lederman E., Miramontes R., Openshaw J., Olson V.A., Karem K.L., Marcinak J., et al. Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: An investigation of potential fomites in the home environment. Vaccine 2009, 27(January (3)):375-377.
3. Eckart R.E., Love S.S., Atwood J.E., Arness M.K., Cassimatis D.C., Campbell C.L., et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004, 44(July (1)):201-205.
4. Kemper A., Davis M., Freed G. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002, March.
5. Upfal M.J., Cinti S. Smallpox vaccination and adverse cardiac events. Emerg Infect Dis 2004, 10(May (5)):961-962. discussion 2.
6. Casey C.G., Iskander J.K., Roper M.H., Mast E.E., Wen X.J., Torok T.J., et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005, 294(December (21)):2734-2743.
7. Kolhapure R.M., Deolankar R.P., Tupe C.D., Raut C.G., Basu A., Dama B.M., et al. Investigation of buffalopox outbreaks in Maharashtra State during 1992-1996. Indian J Med Res 1997, 106(November):441-446.
8. Damaso C.R., Esposito J.J., Condit R.C., Moussatche N. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 2000, 277(November (2)):439-449.
9. Silva-Fernandes A.T., Travassos C.E., Ferreira J.M., Abrahao J.S., Rocha E.S., Viana-Ferreira F., et al. Natural human infections with Vaccinia virus during bovine vaccinia outbreaks. J Clin Virol 2009, 44(April (4)):308-313.
10. Kurth A., Straube M., Kuczka A., Dunsche A.J., Meyer H., Nitsche A. Cowpox virus outbreak in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) with a time-delayed infection to humans. PLoS One 2009, 4(9):e6883.
11. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human monkeypox incidence 30years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A, 14;107(September (37)):16262-7.
12. Lederman E.R., Reynolds M.G., Karem K., Braden Z., Learned-Orozco L.A., Wassa-Wassa D., et al. Prevalence of antibodies against orthopoxviruses among residents of Likouala region, Republic of Congo: evidence for monkeypox virus exposure. Am J Trop Med Hyg 2007, 77(December (6)):1150-1156.
13. Chen N., Li G., Liszewski M.K., Atkinson J.P., Jahrling P.B., Feng Z., et al. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 2005, 340(September (1)):46-63.
14. Lewis M.W., Graham M.B., Hammarlund E., Hanifin J., Slifka M.K. Monkeypox without exanthem. N Engl J Med 2007, 356(May (20)):2112-2114.
15. Meisinger-Henschel C., Schmidt M., Lukassen S., Linke B., Krause L., Konietzny S., et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol 2007, 88(December (Pt 12)):3249-3259.
16. Blanchard T.J., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998, 79(May (Pt 5)):1159-1167.
17. Ferrier-Rembert A., Drillien R., Tournier J.N., Garin D., Crance J.M. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 2008, 26(March (14)):1794-1804.
18. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428(March (6979)):182-185.
19. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005, 79(June (12)):7845-7851.
20. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., et al. Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010, 78(January (1)):145-153.
21. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009, 27(October (45)):6296-6299.
22. Earl P.L., Cotter C., Moss B., VanCott T., Currier J., Eller L.A., et al. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 2009, 27(September (42)):5885-5895.
23. Rocha C.D., Caetano B.C., Machado A.V., Bruna-Romero O. Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 2004, 7(June (2)):83-94.
24. Wyatt L.S., Earl P.L., Eller L.A., Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 2004, 101(March (13)):4590-4595.
25. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001, 19(27):3700-3709.
26. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Dtsch Med Wochenschr 1974, 99(November (47)):2386-2392.
27. Mahnel H., Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berl Munch Tierarztl Wochenschr 1994, 107(August (8)):253-256.
28. Cosma A., Nagaraj R., Staib C., Diemer C., Wopfner F., Schatzl H., et al. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retroviruses 2007, 23(June (6)):782-793.
29. Jones T. IMVAMUNE an attenuated modified vaccinia Ankara virus vaccine for smallpox infection. Curr Opin Mol Ther 2008, 10(August (4)):407-417.
30. Artenstein A.W. New generation smallpox vaccines: a review of preclinical and clinical data. Rev Med Virol 2008, 18(July-August (4)):217-231.
31. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 2003, 100(August (16)):9458-9463.
32. Roper R.L. Characterization of the vaccinia virus A35R protein and its role in virulence. J Virol 2006, 80(1):306-313.
33. Rehm K.E., Jones G.J., Tripp A.A., Metcalf M.W., Roper R.L. The poxvirus A35 protein is an immunoregulator. J Virol 2010, 84(January (1)):418-425.
34. Rehm K.E., Connor R.F., Jones G.J., Yimbu K., Roper R.L. Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology 2010, 397(February (1)):176-186.
35. Roper R.L., Payne L.G., Moss B. Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol 1996, 70:3753-3762.
36. Roper R.L. Rapid preparation of vaccinia virus DNA template for analysis and cloning by PCR. Methods Mol Biol 2004, 269:113-118.
37. Clark R.H., Kenyon J.C., Bartlett N.W., Tscharke D.C., Smith G.L. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 2006, 87(January (Pt 1)):29-38.
38. Chaudhri G., Panchanathan V., Bluethmann H., Karupiah G. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 2006, 80(July (13)):6339-6344.
39. Xu R., Johnson A.J., Liggitt D., Bevan M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004, 172(May (10)):6265-6271.
40. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005, 341(October (1)):91-101.
41. Gherardi M.M., Ramirez J.C., Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol 2003, 84(August (Pt 8)):1961-1972.
42. See R.H., Zakhartchouk A.N., Petric M., Lawrence D.J., Mok C.P., Hogan R.J., et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 2006, 87(March (Pt 3)):641-650.
43. Jing L., Chong T.M., McClurkan C.L., Huang J., Story B.T., Koelle D.M. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol 2005, 175(December (11)):7550-7559.
44. Jones-Trower A., Garcia A., Meseda C.A., He Y., Weiss C., Kumar A., et al. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology 2005, September.
45. Johnson K.L., Ovsyannikova I.G., Mason C.J., Bergen H.R., Poland G.A. Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine 2009, 28(December (1)):38-47.
46. Jin B., Wang R.Y., Qiu Q., Sugauchi F., Grandinetti T., Alter H.J., et al. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology 2007, 122(September (1)):15-27.
47. Oyoshi M.K., Elkhal A., Kumar L., Scott J.E., Koduru S., He R., et al. Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. Proc Natl Acad Sci U S A 2009, 106(September (35)):14954-14959.
48. Scott J.E., ElKhal A., Freyschmidt E.J., MacArthur D.H., McDonald D., Howell M.D., et al. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation. J Allergy Clin Immunol 2007, 120(December (6)):1382-1388.
49. Becker Y. Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity. Virus Genes 2003, 27(December (3)):269-282.
50. Sharma D.P., Ramsay A.J., Maguire D.J., Rolph M.S., Ramshaw I.A. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 1996, 70(October (10)):7103-7107.
51. Yao Y., Li P., Singh P., Thiele A.T., Wilkes D.S., Renukaradhya G.J., et al. Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell Immunol 2007, 246(April (2)):92-102.